**ASCO ANNUAL MEETING 2019 - SWOG ABSTRACTS**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Study** | **Abstract Title/Citation/Abstract Link** | **Authors**  | **Num-ber** | **Session Title/ Session Type/ Date/ Time/ Location**  |
| **SWOG-LED STUDIES** |
| S0307 | Factors associated with osteonecrosis of the jaw in women with breast cancer receiving high-dose bisphosphonates to prevent breast cancer metastases as part of the SWOG 0307 trial. J Clin Oncol 37, 2019 (suppl; abstr 552). <http://abstracts.asco.org/239/AbstView_239_266879.html>  | D Kizub, J Miao, MM Schubert, AHG Paterson, M Clemons, EC Dees, JN Ingle, CI Falkson, W Barlow, GN Hortobagyi, JR Gralow | 552, Board #44 | Breast Cancer Local/ Regional/ Adjuvant; Poster Session; 6/2/2019, 8:00 AM-11:00 AM; Hall A |
| S0702 | Osteonecrosis of the jaw in patients with cancer receiving zoledronic acid for bone metastases: SWOG S0702, NCT00874211. J Clin Oncol 37, 2019 (suppl; abstr 11502). <http://abstracts.asco.org/239/AbstView_239_261887.html>  | CH Van Poznak, JM Unger, A Darke, CM Moinpour, RA Bagramian, MM Schubert, LK Hansen, JD Floyd, SR Dakhil, DL Lew, JL Wade, MJ Fisch, LN Henry, DL Hershman, JR Gralow | 11502 | Symptoms and Survivorship; Oral Abstract Session; 06/03/2019, 8:00 AM - 11:00 AMPresentation Time: 8:24 AM - 8:36 AM; S102 |
| S1105 | Randomized trial of text messaging (TM) to reduce early discontinuation of aromatase inhibitor (AI) therapy in women with breast cancer: SWOG S1105. J Clin Oncol 37, 2019 (suppl; abstr 6516)<http://abstracts.asco.org/239/AbstView_239_253469.html>  | DL Hershman, JM Unger, G Hillyer, A Moseley, KB Arnold, SR Dakhil, BT Esparaz, MC Kuan, ML Graham, II, DM Lackowski, WJ Edenfield, ZR Dayao, JR Gralow, SD Ramsey, AI Neugut | 6516 | Health Services Research, Clinical Informatics, and Quality of Care II; Oral Abstract Session; 6/2/2019, 8:00 AM-11:00 AM; S404 |
| S1206 | S1206: A dose-finding study followed by a phase II randomized placebo-controlled trial of chemoradio-therapy (CRT) with or without veliparib in stage III non-small cell lung cancer (NSCLC). J Clin Oncol 37, 2019 (suppl; abstr 8523). <http://abstracts.asco.org/239/AbstView_239_248681.html>  | A Argiris, J Miao, M Cristea, AM Chen, J Sands, RH Decker, SN Gettinger, M Daly, BA Faller, KS Albain, RH Yanagihara, LL Garland, LA Byers, D Wang, M Koczywas, M Redman, K Kelly, D Gardara | 8523, Board #279 | Lung Cancer—Non-Small Cell Local-Regional/Small Cell/ Other Thoracic Cancers; Poster Session: 6/2/2019, 8:00 AM-11:00 AM; Hall A |
| S1314 | SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer. J Clin Oncol 37, 2019 (suppl; abstr 4506). <http://abstracts.asco.org/239/AbstView_239_260635.html>  | TW Flaig, CM Tangen, S Daneshmand, AS Alva, SP Lerner, MS Lucia, DJ McConkey, D Theodorescu, A Goldkorn, MI Milowsky, RC Bangs, GR MacVicar, BR Bastos, D Gustafson, M Plets, IM Thompson | 4506 | Genitourinary (Nonprostate) Cancer; Oral Abstract Session: 6/3/2019, 8:00 AM-11:00 AM; Arie Crown Theater  |
| S1400G  | A Phase II Study of Talazoparib (BMN 673) in Patients with Homologous Recombination Repair Deficiency (HRRD) Positive Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study, S1400G). J Clin Oncol 37, 2019 (suppl; abstr 9022). <http://abstracts.asco.org/239/AbstView_239_260823.html>  | TK Owonikoko, MW Redman, LA Byers, FR Hirsch, PC Mack,LH Schwartz, JD Bradley, T Stinchcombe, NB Leighl, T AlBaghdadi, P Lara Jr., J Miao, K Kelly, SS Ramalingam, RS Papadimitrakopoulou, DR Gandara | 9022, Board #345 | Lung Cancer—Non-Small Cell Metastatic; Poster Discussion Session: 6/2/2019, Poster Display: 8:00 AM-11:00 AM; Poster Discussion: 4:30 PM-6:00 PM; Hall D1 |
| S1400I |  A phase III randomized study of nivolumab plus ipilimumab versus nivolumab for previously treated patients with stage IV squamous cell lung cancer and no matching biomarker (Lung-MAP Sub-Study S1400I, NCT02785952). J Clin Oncol 37, 2019 (suppl; abstr 9014).<http://abstracts.asco.org/239/AbstView_239_262563.html>  | LA Bazhenova, M Redman, S Gettinger, F Hirsch, P Mack, LH Schwartz, D Gandara, JD Bradley, TE Stinchcombe, N Leighl, S Ramalingam, SS Tavernier, K Minichiello, K Kelly, V Papadimitrakopoulou, RS Herbst | 9014, Board #337 | Lung Cancer —Non-Small Cell Metastatic; Poster Discussion Session; 6/2/2019, Poster Display: 8:00 AM-11:00 AM; Poster Discussion: 4:30 PM-6:00PM, Hall D1HH |
| S1400K | Phase II study of ABBV-399 (Process II) in patients with C-MET positive stage IV/recurrent lung squamous cell cancer (SCC): LUNG-MAP sub-study S1400K (NCT03574753). J Clin Oncol 37, 2019 (suppl; abstr 9075). <http://abstracts.asco.org/239/AbstView_239_263683.html>  | SN Waqar, MW Redman, SM Arnold, FR Hirsch, PC Mack, LHSchwartz, DR Gandara, T Stinchcombe, NB Leighl, SS Ramalingam, SH Tanna, RS Raddin, K Minichiello, K Kelly, JD Bradley, RS Herbst, V Papadimitrakopoulou | 9075, Board #398 | Lung Cancer—Non-Small Cell Metastatic; Poster Session;6/2/2019, 8:00 AM-11:00 AM; Hall A |
| S1417CD | Design and accrual of S1417CD: Development of a prospective financial impact assessment tool in patients with metastatic colorectal cancer (mCRC). J Clin Oncol 37, 2019 (suppl; abstr TPS6652). <http://abstracts.asco.org/239/AbstView_239_251625.html>  | V Shankaran, JM Unger, AK Darke, JM Suga, JL Wade, III, PJ Kourlas, SR Chandana, MA O’Rourke, SP Satti, D Liggett, DL Hershman, SD Ramsey | TPS6652, Board #441b | Health Services Research, Clinical Informatics, and Quality of Care; Poster Session; 6/1/2019, 1:15 PM-4:15 PM, Hall A |
| S1505 | SWOG S1505: Initial findings on eligibility and neoadjuvant chemotherapy experience with mFOLFIRINOX versus gemcitabine/nab-paclitaxel for resectable pancreatic adenocarcinoma. J Clin Oncol 37, 2019 (suppl; abstr 4137). <http://abstracts.asco.org/239/AbstView_239_268327.html>  | DPS Sohal, D Lew, SA Ahmad, NS Gandhi, MS Beg, A Wang-Gillam, JL Wade III, KA Guthrie, AM Lowy, PA Philip, HS Hochster | 4137, Board #242 | Gastrointestinal (Noncolorectal) Cancer; Poster Session; 6/3/2019, 8:00 AM-11:00 AM; Hall A |
| S1507 | S1507: Phase II study of docetaxel and trametinib in patients with G12C or non-G12C KRAS mutation positive (+) recurrent non-small cell lung cancer (NSCLC). J Clin Oncol 37, 2019 (suppl; abstr 9021). <http://abstracts.asco.org/239/AbstView_239_251039.html>  | SM Gadgeel, J Miao, JW Riess, PC Mack, GJ Gerstner, TF Burns, A Taj, WL Akerley, III, K Dragnev, J Moon, DR Gandara, K Kelly | 9021, Board #344 | Lung Cancer—Non-Small Cell Metastatic; Poster Discussion Session: 6/2/2019, Poster Display: 8:00 AM-11:00 AM; Poster Discussion: 4:30 PM-6:00 PM; Hall D1 |
| S1513  | Randomized phase II study of 2nd line modified FOLFIRI with PARP inhibitor ABT-888 (Veliparib) (NSC-737664) versus FOLFIRI in metastatic pancreatic cancer (mPC): SWOG S1513. J Clin Oncol 37, 2019 (suppl; abstr 4014). <http://abstracts.asco.org/239/AbstView_239_260973.html>  | EG Chiorean, KA Guthrie, PA Philip, EM Swisher, F Jalikis, MJ Pishvaian, J Berlin, MS Noel, JM Suga, I Garrido-Laguna, D Backlund Cardin, DL Lew, AM Lowy, HS Hochster | 4014, Board #119 | Gastrointestinal (Noncolorectal) Cancer; Poster Discussion Session: 6/3/2019, Poster Display: 8:00 AM-11:00 AM; Poster Discussion: 3:00 PM-4:30 PM; Hall A |
| S1609 | SWOG 1609 (DART): A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors. J Clin Oncol 37, 2019 (suppl; abstr TPS2658). <http://abstracts.asco.org/239/AbstView_239_260005.html>  | SP Patel, M Othus, YK Chae, F Giles, J Hayward, CM McLeod, HX Chen, E Sharon, E Mayerson, CW Ryan, M Plets, CD Blanke, R Kurzrock  | TPS2658, Board #295a | Developmental Immunotherapy and Tumor Immunobiology; Poster Session: 6/1/2019, 8:00 AM-11:00 AM; Hall A |
| Dataset | Association of baseline cardiovascular risk factors and healthcare utilization and costs in elderly breast cancer patients enrolled in SWOG clinical trials. J Clin Oncol 37, 2019 (suppl; abstr 11508). <http://abstracts.asco.org/239/AbstView_239_253325.html>  | DL Hershman, C Till, JD Wright, M Accordino, R Vaidya; WE Barlow, S Ramsey, JM Unger | 11508 | Symptoms and Survivorship; Oral Abstract Session; 6/3/2019, 8:00 AM-11:00 AM; S102 |
| Dataset | Sex differences in adverse event reporting in SWOG chemotherapy, biologic/immunotherapy, and targeted agent cancer clinical trials. J Clin Oncol 37, 2019 (suppl; abstr 11588). <http://abstracts.asco.org/239/AbstView_239_257521.html>  | JM Unger, R Vaidya, KS Albain, M LeBlanc, LM Minasian, C Gotay, NL Henry, MJ Fisch, SD Ramsey, CD Blanke, GH Lyman, DL Hershman | 11588, Board #280 | Symptoms and Survivorship; Poster Session; 6/3/2019, 1:15 PM-4:15 PM; Hall A |
| Dataset | The impact of NCI-sponsored network group clinical trials on guideline care and new drug indications. J Clin Oncol 37, 2019 (suppl; abstr 6604). <http://abstracts.asco.org/239/AbstView_239_259327.html>  | JM Unger, VT Nghiem, DL Hershman, R Vaidya, M LeBlanc, CD Blanke | 6604 Board #295 | Health Services Research, Clinical Informatics, and Quality of Care; Poster Session; 6/1/2019, 1:15 PM-4:15 PM; Hall A |
| **SWOG CO-LED STUDY (SWOG/Alliance)** |
| C/S80405 | Associations of Insulin-Like Growth Factor Binding Proteins and Adiponectin with Disease Progression and Mortality in Metastatic Colorectal Cancer: Results from CALGB/SWOG 80405 (Alliance). J Clin Oncol 37, 2019 (suppl; abstr 3035). <http://abstracts.asco.org/239/AbstView_239_247819.html>  | BJ Guercio, AP Venook, S Zhang, F-S Ou, DNiedzwiecki, H-JLenz, F Innocenti, M Pollak, AB Nixon, MR Mahoney, BH O'Neil, JE Shaw, BN Polite, CS Denlinger, JN Atkins, RM Goldberg, RJ Mayer, CD Blanke, CS Fuchs, JA Meyerhardt | 3035, Board #27 | Developmental Therapeutics and Tumor Biology (Nonimmuno); Poster Session6/1/19, 8:00 AM - 11:00 AM;Hall A |
| **OTHER GROUP-LED** |
| A021202 | Randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202). J Clin Oncol 37, 2019 (suppl; abstr 4005). <http://abstracts.asco.org/239/AbstView_239_247995.html>  | EK Bergsland, MR Mahoney, TR Asmis, N Hall, P Kumthekar, ML Maitland, D Niedzwiecki, AB Nixon, EM O'Reilly, LH Schwartz, JA Sloan, J Strosberg, JA Meyerhardt |  4005 | Gastrointestinal (Noncolorectal) Cancer;Oral Abstract Session; 6/2/2019; 9:45 AM-12:45 PM; Arie Crown Theater |
| A031201 | Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol 37, 2019 (suppl; abstr 5008). <http://abstracts.asco.org/239/AbstView_239_260395.html>  | MJ Morris, G Heller, A Bryce, A Armstrong, H Beltran, O Hahn, EC McGary, P Mehan, B Roth, H Xiao, ME Taplin, CJ Ryan, S Halabi, E Small  | 5008 | Genitourinary (Prostate) Cancer; Oral Abstract Session; 5/31/2019, 2:45 PM-5:45 PM; Arie Crown Theater |
| A091404 | Alliance A091404: A phase II study of enzalutamide (NSC# 766085) for patients with androgen receptor-positive salivary cancers. J Clin Oncol 37, 2019 (suppl; abstr 6020). <http://abstracts.asco.org/239/AbstView_239_264543.html>  | AL Ho, NR Foster, AJ Zoroufy, F Worden, K Price, D Adkins, D Bowles, H Kang, B Burtness, Er Sherman, R Morton, N Katabi, P Munster, GK Schwartz | 6020,Board #9 | Head and Neck Cancer; Poster Discussion Session; 6/1/2019, Poster Display; 1:15 PM-4:15 PM; Poster Discussion: 4:30 PM-6:00 PM;S100a  |
| C40603 | CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) and bevacizumab (Bev) in triple-negative breast cancer (TNBC). J Clin Oncol 37, 2019 (suppl; abstr 591).<http://abstracts.asco.org/239/AbstView_239_270035.html>  | WM Sikov, M-Y C Polley, EL Twohy, CM Perou, B Singh, DA Berry, SM Tolaney, G Somlo, ER Port, R Qamar, K Sturtz, E Mamounas, M Golshan, JR Bellon, D Collyar, OM Hahn, CA Hudis, EP Winer, A Partridge, LA Carey | 591, Board #83  | Breast Cancer—Local/ Regional/Adjuvant; Poster Session; 6/2/2019, 8:00 AM-11:00 AM; Hall A  |
| C90203 | CALGB 90203 (Alliance): Radical prostatectomy (RP) with or without neoadjuvant chemohormonal therapy (CHT) in men with clinically localized, high-risk prostate cancer (CLHRPC). J Clin Oncol 37, 2019 (suppl; abstr 5079). <http://abstracts.asco.org/239/AbstView_239_264161.html>  | JA Eastham, G Heller, S Halabi, P Monk, SK Clinton, R Zelig Szmulewitz, J Coleman, M Gleave, CP Evans, DW Hillman, H Beltran, M-E Taplin, OM Hahn, JK Parsons, EJ Small, J Mohler, MJ Morris | 5079, Board #191 | Genitourinary (Prostate) Cancer; Poster Session; 6/1/2019, 1:15 PM-4:15 PM; Hall A |
| C90601 | CALGB 90601 (Alliance): Randomized, double blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma. J Clin Oncol 37, 2019 (suppl; abstr 4503). <http://abstracts.asco.org/239/AbstView_239_258121.html>  | J Rosenberg, KV Ballman, S Halabi, C Watt, OM Hahn, PD Steen, R Dreicer, TW Flaig, W M Stadler, C Sweeney, A Mortazavi, MJ Morris | 4503 | Genitourinary Non-Prostate Cancer; Oral Abstract Session; 6/3/19; 8:00 AM -11:00 AM;Arie Crown Theater |
| E1609 | United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-α2b for resected high-risk. J Clin Oncol 37, 2019 (suppl; abstr 9504). <http://abstracts.asco.org/239/AbstView_239_250625.html>  | AA Tarhini, S Lee, FS HodiUN Rao, GI Cohen, O HamidLF Hutchins, JA Sosman, HM Kluger, VK.Sondak, HB Koon, DP Lawrence, KL Kendra, DR Minor, C Lee, MR Albertini, LE Flaherty, T Petrella, JM Kirkwood | 9504 | Melanoma/Skin Cancers; Oral Abstract Session; 6/4/2019, 9:45 AM-12:45 PM; S406  |
| E2810 | Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810). J Clin Oncol 37, 2019 (suppl; abstr 4502). <http://abstracts.asco.org/239/AbstView_239_251081.html>  | LJ Appleman, M Puligandla, SK Pal, W Harris, N Agarwal, BA Costello, CW Ryan, M Pins, J Kolesar, DA Vaena, RA Parikh, M Hashmi, JP Dutcher, RS DiPaola, NB Haas, MA Carducci | 4502 | Genitourinary (Nonprostate) Cancer; Oral Abstract Session; 6/3/2019, 8:00 AM-11:00 AM; Arie Crown Theater  |
| E3805 | HSD3B1 and Overall Survival (OS) in Men with Low-Volume (LV) Metastatic Prostate Cancer (PCa) Treated with Androgen Deprivation Therapy (ADT) or Chemohormonal Therapy in the CHAARTED Randomized Trial. J Clin Oncol 37, 2019 (suppl; abstr 5020). <http://abstracts.asco.org/239/AbstView_239_266005.html>  | JWD Hearn, C Sweeney, N Almassi, CA Reichard, CA Reddy, B Hobbs, DF Jarrard, Y-H Chen, R Dreicer, JA Garcia, MA Carducci, RS DiPaola, N Sharifi | 5020, Board #132 | Genitourinary (Prostate) Cancer; Poster Discussion Session; 6/1/2019, Poster Display: 1:15 PM-4:15 PM, Hall A;Poster Discussion: 4:30 PM-6:00 PM, Arie Crown Theater |
| ECOG PAACT-1 | Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx. J Clin Oncol 37, 2019 (suppl; abstr 503). <http://abstracts.asco.org/239/AbstView_239_264479.html>  | JA Sparano, RJ Gray, DF Makower, TG Lively, TJ Saphner, MM Keane, HL Gomez, PS Reddy, TF Goggins, IA Mayer, D Toppmeyer, A Brufsky, MP Goetz, DF Hayes, EC Dees, KI Pritchard, CE Geyer, JA Olson, KS Albain, GW Sledge  | 503 | Breast Cancer—Local/ Regional/Adjuvant; Oral Abstract Session; 6/3/2019, 9:45 AM-12:45 PM; Hall D2 |
| EA3A06 | E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma. J Clin Oncol 37, 2019 (suppl; abstr 8001). <http://abstracts.asco.org/239/AbstView_239_258227.html>  | S Lonial, S Jacobus, M Weiss, S Kumar, R Orlowski, J Kaufman, A Yacoub, F Buadi, T O’Brien, J Matous, D Anderson, R Emmons, M Dhodapkar, L Wagner, SV Rajkumar | 8001 | Hematologic Malignancies—Plasma Cell Dyscrasia; Oral Abstract Session; 6/2/2019, 9:45 AM-12:45 PM; E451 |
| EA8143 | PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143). J Clin Oncol 37, 2019 (suppl; abstr TPS4597). <http://abstracts.asco.org/239/AbstView_239_259921.html>  | LC Harshman, M Puligandla, NB Haas, M Allaf, CG Drake, DF McDermott, S Signoretti, D Cella, RT Gupta, BM Shuch, TK Choueiri, P Lara, A Kapoor, DYC Heng, MAS Jewett, V Masters, M Dror Michaelson, B Leibovich, D Maskens,MA Carducci | TPS4597, Board #417b | Genitourinary (Nonprostate) Cancer; Poster Session6/3/19, 1:15 PM - 4:15 PM; Hall A  |